

**REGISTERED NUMBER: 02454226 (England and Wales)**

**Strategic Report, Report of the Directors and  
Financial Statements for the Year Ended 31 December 2016  
for  
IDEXX Laboratories Limited**

**Contents of the Financial Statements  
for the Year Ended 31 December 2016**

---

	<b>Page</b>
<b>Company Information</b>	<b>1</b>
<b>Strategic Report</b>	<b>2</b>
<b>Report of the Directors</b>	<b>3</b>
<b>Statement of Directors' Responsibilities</b>	<b>5</b>
<b>Report of the Independent Auditors</b>	<b>6</b>
<b>Statement of Comprehensive Income</b>	<b>8</b>
<b>Statement of Financial Position</b>	<b>9</b>
<b>Statement of Changes in Equity</b>	<b>10</b>
<b>Notes to the Financial Statements</b>	<b>11</b>

---

**IDEXX Laboratories Limited**  
**Company Information**  
**for the Year Ended 31 December 2016**

---

**DIRECTORS:**

P Tye  
J Morton  
J Studer  
B P McKeon

**SECRETARIES:**

J Studer  
Reed Smith Corporate Services Limited

**REGISTERED OFFICE:**

Grange House  
Sandbeck Way  
Wetherby  
West Yorkshire  
LS22 7DN

**REGISTERED NUMBER:**

02454226 (England and Wales)

**AUDITORS:**

The Fish Partnership  
Chartered Accountants  
& Statutory Auditor  
The Mill House  
Boundary Road  
Loudwater  
High Wycombe  
Bucks.  
HP10 9QN

**Strategic Report  
for the Year Ended 31 December 2016**

---

The directors present their strategic report for the year ended 31 December 2016.

IDEXX Laboratories UK Ltd. ("the Company") is a fully owned subsidiary of IDEXX Europe BV. The ultimate parent Company is IDEXX Laboratories Inc. The Company's main activities include sales & marketing of veterinary diagnostic products, veterinary laboratory services and water diagnostic products.

**REVIEW OF BUSINESS**

Net sales for 2016 were £63,399,000, an increase of 20% over 2015.

In 2016 the Company received a one-time payment of £1,182,000 (2015: £333,000) from related companies, related to the non-exclusive perpetual license of the LYNXX software. LYNXX is the reference laboratory information management system developed by the Company and first implemented in the UK reference laboratories in 2010.

Net profit/loss (after tax) went up from a loss of £56,000 2015 to a profit of £1,769,000 in 2016.

The companion animal veterinary diagnostics business grew strongly by 18% in 2016. The business continued to successfully place its instruments into veterinary clinics and the sales grew accordingly. This, coupled with the placements in 2015 and improvements in utilization of the instruments, means that consumables revenue became an important recurring source.

At the same time our laboratory services have seen record sample volumes in the year and sales have also grown dynamically.

Our water diagnostics business has again delivered strong results, with revenues now topping £6,000,000 and growth of 6%.

**PRINCIPAL RISKS AND UNCERTAINTIES**

The Directors have assessed the Company's price, credit and liquidity risks all of which are considered to be low.

**FUTURE DEVELOPMENTS**

For 2017 the business continues to focus on top line growth however, it is also looking to improve gross and operating margins.

The Company has increased the number of personnel in 2016, from 240 in 2015 to a total of 254. For coming years we expect to add personnel in selected areas while continuing to seek efficiency improvements to maintain expectations of continued business growth and leverage.

**ON BEHALF OF THE BOARD:**

J Morton - Director

29 September 2017

**Report of the Directors  
for the Year Ended 31 December 2016**

---

The directors present their report with the financial statements of the company for the year ended 31 December 2016.

**DIVIDENDS**

An interim dividend of £1,250,000 per share was paid on 21 December 2016. The directors recommend that no final dividend be paid.

The total distribution of dividends for the year ended 31 December 2016 will be £ 2,500,000 .

The profit for the year, after taxation, amounted to £1,769,151.

**DIRECTORS**

The directors shown below have held office during the whole of the period from 1 January 2016 to the date of this report.

P Tye  
J Morton

Other changes in directors holding office are as follows:

M Koeleman - resigned 31 March 2016  
M Williams - appointed 31 March 2016 - resigned 2 November 2016  
J Studer - appointed 31 March 2016

B P McKeon was appointed as a director after 31 December 2016 but prior to the date of this report.

The company is a wholly owned subsidiary and the interests of the group directors are disclosed in the financial statements of the ultimate parent company.

**FINANCIAL INSTRUMENTS**

Basic financial instruments, including trade and other receivables, cash and bank balances and investments in commercial paper, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of future receipts discounted at a market rate of interest.

Such assets are subsequently carried at amortised cost using the effective interest method.

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in profit or loss.

**EMPLOYEES**

IDEXX takes an utmost care to comply with the Equality Act (2010) to be sure as an employer we provide to our employees the most ethical environment. IDEXX employees have access to a large batch of documentation on our intranet to better understand our code of Ethics and their rights. Thus, our HR department promotes these morals throughout guidelines on multiple topics (i.e.: opportunities, training or employment of disabled persons).

**Report of the Directors  
for the Year Ended 31 December 2016**

---

**STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS**

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

**ON BEHALF OF THE BOARD:**

J Morton - Director

29 September 2017

**Statement of Directors' Responsibilities  
for the Year Ended 31 December 2016**

---

The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

## **Report of the Independent Auditors to the Members of IDEXX Laboratories Limited**

---

We have audited the financial statements of IDEXX Laboratories Limited for the year ended 31 December 2016 on pages eight to eighteen. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

### **Respective responsibilities of directors and auditors**

As explained more fully in the Statement of Directors' Responsibilities set out on page five, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

### **Scope of the audit of the financial statements**

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the directors; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Strategic Report and the Report of the Directors to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

### **Opinion on financial statements**

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2016 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

### **Opinion on other matter prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of our audit, the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements, and has been prepared in accordance with applicable legal requirements. In the light of the knowledge and understanding of the company and its environment, we have not identified any material misstatements in the Strategic Report or the Report of the Directors.



**Report of the Independent Auditors to the Members of  
IDEXX Laboratories Limited**

---

**Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Paul Laird (Senior Statutory Auditor)  
for and on behalf of The Fish Partnership  
Chartered Accountants  
& Statutory Auditor  
The Mill House  
Boundary Road  
Loudwater  
High Wycombe  
Bucks.  
HP10 9QN

29 September 2017

**Statement of Comprehensive Income  
for the Year Ended 31 December 2016**

	Notes	2016 £	2015 £
<b>TURNOVER</b>	3	63,398,879	52,691,185
Cost of sales		<u>47,093,920</u>	<u>39,253,215</u>
<b>GROSS PROFIT</b>		16,304,959	13,437,970
Administrative expenses		<u>13,977,159</u>	<u>13,410,132</u>
<b>OPERATING PROFIT</b>		2,327,800	27,838
Interest receivable and similar income		<u>(4,051)</u>	<u>7,248</u>
		2,323,749	35,086
Interest payable and similar expenses	6	<u>93,516</u>	<u>97,263</u>
<b>PROFIT/(LOSS) BEFORE TAXATION</b>	7	2,230,233	(62,177)
Tax on profit/(loss)	8	<u>461,082</u>	<u>(6,142)</u>
<b>PROFIT/(LOSS) FOR THE FINANCIAL YEAR</b>		1,769,151	(56,035)
<b>OTHER COMPREHENSIVE INCOME</b>		-	-
<b>TOTAL COMPREHENSIVE INCOME FOR THE YEAR</b>		<u>1,769,151</u>	<u>(56,035)</u>

The notes form part of these financial statements

**Statement of Financial Position**  
**31 December 2016**

	Notes	2016 £	£	2015 £	£
<b>FIXED ASSETS</b>					
Intangible assets	10		526,875		660,748
Tangible assets	11		7,209,150		8,708,301
Investments	12		<u>1</u>		<u>1</u>
			7,736,026		9,369,050
<b>CURRENT ASSETS</b>					
Debtors	13	9,541,126		9,011,304	
Cash at bank		<u>69,151</u>		<u>67,255</u>	
		9,610,277		9,078,559	
<b>CREDITORS</b>					
Amounts falling due within one year	14	<u>8,971,269</u>		<u>7,335,992</u>	
<b>NET CURRENT ASSETS</b>			<u>639,008</u>		<u>1,742,567</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			8,375,034		11,111,617
<b>CREDITORS</b>					
Amounts falling due after more than one year	15		(300,354)		(2,190,451)
<b>PROVISIONS FOR LIABILITIES</b>	17		<u>(50,336)</u>		<u>(165,973)</u>
<b>NET ASSETS</b>			<u>8,024,344</u>		<u>8,755,193</u>
<b>CAPITAL AND RESERVES</b>					
Called up share capital	18		2		2
Retained earnings	19		<u>8,024,342</u>		<u>8,755,191</u>
<b>SHAREHOLDERS' FUNDS</b>			<u>8,024,344</u>		<u>8,755,193</u>

The financial statements were approved by the Board of Directors on 29 September 2017 and were signed on its behalf by:

J Morton - Director

The notes form part of these financial statements

**Statement of Changes in Equity  
for the Year Ended 31 December 2016**

	Called up share capital £	Retained earnings £	Total equity £
<b>Balance at 1 January 2015</b>	2	11,311,226	11,311,228
<b>Changes in equity</b>			
Dividends	-	(2,500,000)	(2,500,000)
Total comprehensive income	-	(56,035)	(56,035)
<b>Balance at 31 December 2015</b>	<u>2</u>	<u>8,755,191</u>	<u>8,755,193</u>
<b>Changes in equity</b>			
Dividends	-	(2,500,000)	(2,500,000)
Total comprehensive income	-	1,769,151	1,769,151
<b>Balance at 31 December 2016</b>	<u>2</u>	<u>8,024,342</u>	<u>8,024,344</u>

The notes form part of these financial statements

**Notes to the Financial Statements  
for the Year Ended 31 December 2016**

---

**1. STATEMENT OF COMPLIANCE**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

**2. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements have been prepared under the historical cost convention.

**Financial reporting standard 102 - reduced disclosure exemptions**

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows;
- the requirement of Section 33 Related Party Disclosures paragraph 33.7.

**Preparation of consolidated financial statements**

The financial statements contain information about IDEXX Laboratories Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 401 of the Companies Act 2006 from the requirements to prepare consolidated financial statements as it and its subsidiary undertakings are included by full consolidation in the consolidated financial statements of its ultimate parent, IDEXX Laboratories Inc., a company registered in the United States of America.

**Turnover**

Turnover represents net invoiced sales of goods and services, excluding value added tax.

**Goodwill**

Amortisation is calculated so as to write off the cost of the goodwill, less its estimated residual value, over the useful economic life of the goodwill.

The useful economic life is considered to be 2 to 20 years.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Freehold property	- Straight line over 7 - 40 years
Short leasehold	- Over the period of the lease
Fixtures and fittings	- at varying rates on cost
Computer equipment	- Straight line over 3 - 7 years

**Investments in subsidiaries**

Investments in subsidiary undertakings are recognised at cost.

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2016**

---

**2. ACCOUNTING POLICIES - continued**

**Financial instruments**

Basic financial instruments, including trade and other receivables, cash and bank balances and investments in commercial paper, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of future receipts discounted at a market rate of interest.

Such assets are subsequently carried at amortised cost using the effective interest method.

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in profit or loss.

**Taxation**

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Comprehensive Income, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

**Deferred tax**

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

**Foreign currencies**

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

**Hire purchase and leasing commitments**

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

**Pension costs and other post-retirement benefits**

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

**Notes to the Financial Statements - continued**  
**for the Year Ended 31 December 2016**

**3. TURNOVER**

The turnover and profit (2015 - loss) before taxation are attributable to the one principal activity of the company.

An analysis of turnover by class of business is given below:

	2016 £	2015 £
Veterinary diagnostic products	32,679,685	28,703,103
Veterinary laboratory	23,462,639	17,922,086
Licenses	1,182,320	333,526
Water diagnostic products	6,074,235	5,732,470
	<u>63,398,879</u>	<u>52,691,185</u>

The total turnover of the company for the year has been derived from its principal activity wholly undertaken in the UK and Southern Ireland.

**4. EMPLOYEES AND DIRECTORS**

	2016 £	2015 £
Wages and salaries	9,701,293	9,972,605
Social security costs	1,061,213	976,850
Other pension costs	527,621	433,468
	<u>11,290,127</u>	<u>11,382,923</u>

The average monthly number of employees during the year was as follows:

	2016	2015
Directors	1	1
Supply and marketing diagnostic products	58	60
Veterinary laboratory	195	179
	<u>254</u>	<u>240</u>

**5. DIRECTORS' EMOLUMENTS**

	2016 £	2015 £
Directors' remuneration	<u>199,335</u>	<u>187,207</u>

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes	<u>1</u>	<u>1</u>
------------------------	----------	----------

Certain directors are remunerated by other fellow group companies as they are also directors and officers of other companies within the group. These directors services to the company do not occupy a significant amount of their time. As such these directors do not consider that they have received any remuneration for the incidental services to the company for the year ended 31 December 2016 or 31 December 2015.

**Notes to the Financial Statements - continued**  
**for the Year Ended 31 December 2016**

**6. INTEREST PAYABLE AND SIMILAR EXPENSES**

	2016	2015
	£	£
Interest paid on late tax	5,459	39,163
Loan	88,057	58,100
	<u>93,516</u>	<u>97,263</u>

**7. PROFIT/(LOSS) BEFORE TAXATION**

The profit (2015 - loss) is stated after charging/(crediting):

	2016	2015
	£	£
Other operating leases	594,267	521,972
Depreciation - owned assets	1,782,307	1,718,922
Loss on disposal of fixed assets	47,225	67
Goodwill amortisation	133,873	146,150
Auditor's remuneration	28,245	25,909
Taxation compliance services	3,250	6,580
Foreign exchange differences	<u>(5,122)</u>	<u>64,580</u>

**8. TAXATION****Analysis of the tax charge/(credit)**

The tax charge/(credit) on the profit for the year was as follows:

	2016	2015
	£	£
Current tax:		
UK corporation tax	576,719	-
Deferred tax	<u>(115,637)</u>	<u>(6,142)</u>
Tax on profit/(loss)	<u>461,082</u>	<u>(6,142)</u>



**Notes to the Financial Statements - continued**  
**for the Year Ended 31 December 2016**

**8. TAXATION - continued****Reconciliation of total tax charge/(credit) included in profit and loss**

The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

	2016 £	2015 £
Profit/(loss) before tax	<u>2,230,233</u>	<u>(62,177)</u>
Profit/(loss) multiplied by the standard rate of corporation tax in the UK of 20% (2015 - 20.246%)	446,047	(12,588)
Effects of:		
Expenses not deductible for tax purposes	32,187	38,125
Income not taxable for tax purposes	-	(13,908)
Depreciation in excess of capital allowances	142,532	32,909
Group relief	(33,210)	(14,046)
Revenue expenditure capitalised	(1,410)	(30,492)
Movement in deferred tax	(115,637)	(6,142)
Group relieved Research & Development expenditure credit	(9,427)	-
Total tax charge/(credit)	<u>461,082</u>	<u>(6,142)</u>

The UK Government announced as part of the Finance (No 2) Act 2015, which received Royal Assent on 18 November 2015 that the main rate of corporation tax would be reduced from 20% to 19% from 1 April 2017. In addition as part of the Finance Act 2016, it was further reduced to 17% from 1 April 2020. This will affect the rate at which future UK current tax will be payable.

**9. DIVIDENDS**

	2016 £	2015 £
Ordinary shares of £1 each		
Interim	<u>2,500,000</u>	<u>2,500,000</u>

**10. INTANGIBLE FIXED ASSETS**

	Goodwill £
<b>COST</b>	
At 1 January 2016	
and 31 December 2016	<u>2,248,942</u>
<b>AMORTISATION</b>	
At 1 January 2016	1,588,194
Amortisation for year	133,873
At 31 December 2016	<u>1,722,067</u>
<b>NET BOOK VALUE</b>	
At 31 December 2016	<u>526,875</u>
At 31 December 2015	<u>660,748</u>

**Notes to the Financial Statements - continued**  
**for the Year Ended 31 December 2016**

**11. TANGIBLE FIXED ASSETS**

	Freehold property £	Short leasehold £	Fixtures and fittings £	Computer equipment £	Totals £
<b>COST</b>					
At 1 January 2016	3,702,276	453,266	5,286,234	8,378,097	17,819,873
Additions	6,710	125,361	59,486	138,825	330,382
Disposals	-	-	(874,667)	-	(874,667)
Reclassification/transfer	-	-	66,876	-	66,876
At 31 December 2016	<u>3,708,986</u>	<u>578,627</u>	<u>4,537,929</u>	<u>8,516,922</u>	<u>17,342,464</u>
<b>DEPRECIATION</b>					
At 1 January 2016	899,191	282,368	3,523,072	4,406,941	9,111,572
Charge for year	116,372	40,760	411,686	1,213,489	1,782,307
Eliminated on disposal	-	-	(827,442)	-	(827,442)
Reclassification/transfer	-	-	66,877	-	66,877
At 31 December 2016	<u>1,015,563</u>	<u>323,128</u>	<u>3,174,193</u>	<u>5,620,430</u>	<u>10,133,314</u>
<b>NET BOOK VALUE</b>					
At 31 December 2016	<u>2,693,423</u>	<u>255,499</u>	<u>1,363,736</u>	<u>2,896,492</u>	<u>7,209,150</u>
At 31 December 2015	<u>2,803,085</u>	<u>170,898</u>	<u>1,763,162</u>	<u>3,971,156</u>	<u>8,708,301</u>

**12. FIXED ASSET INVESTMENTS**

	Shares in group undertakings £
<b>COST</b>	
At 1 January 2016 and 31 December 2016	<u>1</u>
<b>NET BOOK VALUE</b>	
At 31 December 2016	<u>1</u>
At 31 December 2015	<u>1</u>

The company's investments at the Statement of Financial Position date in the share capital of companies include the following:

**Vet Med Lab (UK) Limited**

Registered office:

Nature of business: Dormant

	% holding	2016 £	2015 £
Class of shares:			
Ordinary shares	100.00		
Aggregate capital and reserves		<u>1</u>	<u>1</u>

Notes to the Financial Statements - continued  
for the Year Ended 31 December 2016**13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2016 £	2015 £
Trade debtors	7,933,639	7,745,779
Provision for doubtful debts	-	(80,312)
Amounts owed by group undertakings	1,273,378	997,699
Other debtors	31,868	36,842
Prepayments and accrued income	302,241	311,296
	<u>9,541,126</u>	<u>9,011,304</u>

**14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2016 £	2015 £
Trade creditors	178,889	281,949
Amounts owed to group undertakings	2,478,276	450,370
Tax	393,469	(113,500)
Social security and other taxes	64,610	56,755
VAT	1,678,219	1,443,729
Other creditors	1,822,119	3,335,662
Accruals and deferred income	2,355,687	1,881,027
	<u>8,971,269</u>	<u>7,335,992</u>

**15. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR**

	2016 £	2015 £
Amounts owed to group undertakings	-	2,000,000
Accruals and deferred income	300,354	190,451
	<u>300,354</u>	<u>2,190,451</u>

**16. LEASING AGREEMENTS**

Minimum lease payments under non-cancellable operating leases fall due as follows:

	2016 £	2015 £
Within one year	339,209	391,511
Between one and five years	673,226	767,046
In more than five years	57,509	173,865
	<u>1,069,944</u>	<u>1,332,422</u>

**17. PROVISIONS FOR LIABILITIES**

	2016 £	2015 £
Deferred tax	<u>50,336</u>	<u>165,973</u>

Notes to the Financial Statements - continued  
for the Year Ended 31 December 2016

17. **PROVISIONS FOR LIABILITIES - continued**

	Deferred tax £
Balance at 1 January 2016	165,973
Movement in provision	(115,637)
Balance at 31 December 2016	<u>50,336</u>

18. **CALLED UP SHARE CAPITAL**

Allotted, issued and fully paid:		Nominal value:	2016	2015
Number:	Class:		£	£
2	Ordinary	£1	<u>2</u>	<u>2</u>

19. **RESERVES**

	Retained earnings £
At 1 January 2016	8,755,191
Profit for the year	1,769,151
Dividends	(2,500,000)
At 31 December 2016	<u>8,024,342</u>

20. **ULTIMATE PARENT COMPANY**

The company was controlled throughout the current and previous year by its immediate parent company, IDEXX Europe BV, a company incorporated in the Netherlands. The ultimate parent company is IDEXX Laboratories Inc, a company incorporated in the USA. Copies of the group accounts incorporating the results of the company are available from IDEXX Laboratories Inc, One Idexx Drive, Westbrook, Maine 04092, USA.

21. **RELATED PARTY DISCLOSURES**

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.